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The current first-line treatment for advanced metastatic prostate cancer, i.e. docetaxel-
based therapy, is only marginally effective. The aim of the present study was to determine
whether such therapy can be improved by combining docetaxel with Aneustat (OMN54), a
multivalent botanical drug candidate shown to have anti-prostate cancer activity in pre-
liminary in vitro experiments, which is currently undergoing a Phase-I Clinical Trial. Hu-
man metastatic, androgen-independent C4-2 prostate cancer cells and NOD-SCID mice
bearing PTEN-deficient, metastatic and PSA-secreting, patient-derived subrenal capsule
LTL-313H prostate cancer tissue xenografts were treated with docetaxel and Aneustat,
alone and in combination. In vitro, Aneustat markedly inhibited C4-2 cell replication in a
dose-dependent manner. When Aneustat was combined with docetaxel, the growth inhi-
bitions of the drugs were essentially additive. In vivo, however, the combination of doce-
taxel and Aneustat enhanced anti-tumor activity synergistically and very markedly,
without inducing major host toxicity. Complete growth inhibition and shrinkage of the xe-
nografts could be obtained with the combined drugs as distinct from the drugs on their
own. Analysis of the gene expression of the xenografts using microarray indicated that
docetaxel þ Aneustat led to expanded anticancer activity, in particular to targeting of can-
cer hallmarks that were not affected by the single drugs. Our findings, obtained with a
highly clinically relevant prostate cancer model, suggest, for the first time, that
docetaxel-based therapy of advanced human prostate cancer may be improved by
combining docetaxel with Aneustat.
ª 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.imental Therapeutics, BC
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M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 3 1 1e3 2 23121. Introduction Aneustat (OMN54) is a multifunctional/multitargetedProstate cancer is the most commonly diagnosed non-
cutaneous cancer and one of the leading causes of cancer
death for North American men (Siegel et al., 2012). When the
malignancy is localized to the prostate, surgery and radiation
therapy can be curative. Many patients, however, will experi-
ence local recurrence and progression tometastasis (Fleshner,
2005). As prostate cancer growth in general is androgen-
dependent, androgen ablation therapy of locally advanced,
recurrent or metastatic prostate cancer is usually quite effec-
tive in the first 1e3 years. However, cancers frequently
develop within 18e24 months into a more aggressive, pres-
ently incurable, androgen-independent phenotype, termed
“castration-resistant prostate cancer” (CRPC) (Hotte and
Saad, 2010). The emergence of CRPC typically manifests as ris-
ing serum prostate-specific antigen (PSA) levels (Oh and
Kantoff, 1998). It is well established that the stimulation of
PSA gene expression is mediated by the androgen receptor
(AR), and increasing evidence suggests that the AR plays an
important role in the development of CRPC (Chen et al.,
2004; Mohler et al., 2004). Furthermore, there is an emerging
role in the carcinogenesis and progression of prostate cancer
for the PI3K/AKT pathway (Gao et al., 2012; Li et al., 2005), re-
ported to be involved in cell migration, tissue invasion and
therapy resistance of various types of cancer (Tian et al.,
2010; Tokunaga et al., 2006).
The current standard first-line therapy for highly advanced
metastatic prostate cancer is systemic docetaxel plus predni-
sone chemotherapy adopted in 2004 (McKeage, 2012). Doce-
taxel is a semi-synthetic, second-generation taxane derived
from the bark of the European yew tree, Taxus baccata
(Mangatal et al., 1989). Its main mode of anticancer action is
based on interference with microtubule dynamics (assembly
and disassembly) (Tabaczar et al., 2010), leading to inhibition
of the progression of cells through the cell cycle (Garcia
et al., 1994; Lavelle et al., 1995). Furthermore, docetaxel can
induce cell apoptosis by altering the expression and phos-
phorylation of members of the Bcl-2 family of proteins
(Pienta, 2001; Stein, 1999). However, treatment with docetaxel
plus prednisone is not curative, is associated with severe side
effects and increases the overall survival of patients only
marginally when compared with the previous standard
mitoxantrone plus prednisone regimen (Tannock et al., 2004).
New therapeutics have been developed, including Abira-
terone acetate, a CYP17 inhibitor (de Bono et al., 2011), and
Enzalutamide (formerly known as MDV3100), an AR inhibitor
(Agarwal et al., 2012), that were approved by the US Food
and Drug Administration (FDA) to treat metastatic CRPC pa-
tients who failed prior docetaxel-containing chemotherapy
(Aragon-Ching, 2012; Logothetis et al., 2011). Various agents
demonstrating additive or synergistic effects in preclinical
studies have also been combined with docetaxel, but overall
survival has so far not been extended compared to the doce-
taxel plus prednisone standard regimen (Antonarakis and
Eisenberger, 2013; McKeage, 2012). Clearly, development of
more effective drugs and novel therapeutic approaches are
of critical importance for improving disease management
and survival of metastatic prostate cancer patients.botanical anti-cancer drug candidate (National Cancer Insti-
tute Drug Dictionary) developed by Omnitura Therapeutics
Inc., USA. It is currently being evaluated in a Phase-I Clinical
Trial in Canada (NCTId: NCT01555242). In a previous study in
our laboratory, treatment with Aneustat alone suppressed
the growth of subrenal LNCaP cell line xenografts markedly
(Supplementary Figure S1). In the present study it was found
that the combination of docetaxel and Aneustat canmarkedly
and synergistically enhance anti-tumor activity in a metasta-
tic prostate cancer tissue xenograft model derived from a pa-
tient’s prostate cancer specimen (www.livingtumorlab.com).
Expression microarray analysis indicated that the combined
use of docetaxel and Aneustat led to expanded anticancer ac-
tivity, in particular to targeting of pathways and cancer hall-
marks, that was not attained when the drugs were used as
single agents.2. Materials and methods
2.1. Materials
Chemicals, solvents and solutions were obtained from Sigma-
eAldrich, Oakville, ON, Canada, unless otherwise indicated.
Aneustat was supplied by Omnitura Therapeutics Inc. (Hen-
derson, NV) and docetaxel was purchased from Sanofi-
Aventis Canada Inc. (Laval, Quebec, Canada).
2.2. Cell culture
Human C4-2 androgen-independent prostate cancer cells, i.e.
metastatic, PTEN-deficient cells derived from the LNCaP cell
line (Sobel and Sadar, 2005; Wu et al., 1998), were obtained
from the Leland W. K. Chung Laboratory (Cedars-Sinai Medi-
cal Center). They were maintained as monolayer cultures in
RPMI-1640 medium supplemented with fetal bovine serum
(FBS; 10%), penicillin (100 units/ml) and streptomycin
(100 mg/ml) at 37 C in a humidified incubator with a 5% CO2
atmosphere.
2.3. In vitro drug efficacy determination
Trypsinized C4-2 cells were seeded into 24-well culture plates
(starting concentration approximately 1  105 cells/ml) and
incubated at 37 C in 5% CO2 for 24 h. Aneustat and docetaxel
(both dissolved in DMSO), were then added to the cultures as
single drugs or in various combinations for a further 48-h in-
cubation to assess the effects of the drugs on cell numbers;
DMSO was used as a vehicle control.
2.4. Animals
Non-obese diabetic severe combined immunodeficiency
(NOD-SCID) mice (males; 6e8 weeks old; body weight,
23e25 g), bred in the BC Cancer Research Centre ARC animal
facility, were housed in sterilemicro-isolator cages under spe-
cific pathogen-free conditions. Food and water were sterilized
prior to use. Temperature (20e21 C) and humidity (50e60%)
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dark. Cages were completely changed once or twice a week.
Animals were handled under sterile conditions. The
maximum tolerated dose of Aneustat was determined using
conventional methodology. Animal care and experiments
were carried out in accordance with the guidelines of the Ca-
nadian Council on Animal Care.
2.5. Prostate cancer xenograft model and treatment
The LTL-313H transplantable, PTEN-deficient, metastatic and
PSA-secreting, patient-derived prostate cancer tissue line
(Choi et al., 2012; Wu et al., 2012) (generation 13) was main-
tained as grafts under renal capsules of male NOD-SCID
mice supplemented with testosterone as previously described
(Watahiki et al., 2011). For experiments, tumors were har-
vested 10 weeks after grafting and pieces of tumor tissue
(2.5  2.5  1.25 mm3) were grafted under the renal capsules
of 36 testosterone-supplemented male mice (6 groups; 6
mice/group; 4 grafts/mouse). The grafts had a 100% engraft-
ment rate with an average tumor volume doubling time of
13e15 days. Increases in the plasma PSA levels of the mice
were used as ameasure of tumor growth. After about 6 weeks,
when levels of w12 ng PSA/ml plasma had been reached, i.e.
equivalent to tumor volumes of 30e50 mm3, the mice were
randomly distributed into 6 groups and treatedwith docetaxel
(i.p.; Q7d/3) and Aneustat (orally; Q1d  5/3) along the
following schedule: (a) vehicle control, (b) docetaxel (5 mg/
kg), (c) Aneustat (1652 mg/kg), (d) docetaxel (5 mg/
kg) þ Aneustat (413 mg/kg), (e) docetaxel (5 mg/
kg) þ Aneustat (826 mg/kg), and (f) docetaxel (5 mg/
kg) þ Aneustat (1652 mg/kg). After 3 weeks, the mice were
euthanized, tumor volumes measured using callipers and tis-
sue sections prepared for histopathological analysis (see
below). Tumor growth of treated animals relative to untreated
animals was used as a measure of antitumor activity, i.e. T/
C ¼ (treated tumor volume3wks  treated tumor volume0wks):(-
control tumor volume3wks e control tumor
volume0wks)  100%, with T/C > 0 indicating tumor growth
and T/C < 0 indicating tumor shrinkage. Tumor growth
inhibition ¼ 100%  T/C.
2.6. Immunohistochemical staining
Preparation of paraffin-embedded tissue sections and immu-
nohistochemical analyses were carried out as previously
described (Wang et al., 2005b). The anti-Cleaved Caspase 3
(Asp175) (5A1E) (#9664, 1:50, rabbit anti-human; Cell Signaling
Technology, Danvers, MA) was used for immunohistochem-
ical staining. All sections used for immunohistochemistry
were lightly counterstained with 5% (w/v) Harris hematoxylin.
Five fields of each slide were randomly chosen and images
taken (400), using an AxioCam HR CCD mounted on an Axi-
oplan 2 microscope and Axiovision 3.1 software (Carl Zeiss,
Canada). Positively stained cells andwhole cells in each image
were counted and the percentage of positive cells was calcu-
lated. Caspase 3 expression could be used as an indicator
of apoptotic activity since a high correlation was found be-
tween caspase 3 expression and apoptotic body counts
(Supplementary Table S1).2.7. Real-time PCR analysis
Total RNAwasextractedusingTrizol reagent (Invitrogen,Carls-
bad, CA) according to the manufacturer’s instructions. RNA
(1 mg) extract was treated with DNase and reverse transcribed
with random primers and Im-Prom II Reverse transcriptase
(Promega, Madison, WI). The cDNA was subjected to quantita-
tive real-time RT-PCR using specific primers for AR and b-actin.
[AR: 50-CCTGGCTTCCGCAACTTACAC, 30-GGACTTGTG-
CATGCGGTACTCA, b-actin: 50-CCCAGCCATGTACGTTGCTA,
30-AGGGCATACCCCTCGTAGATG]. It was performed in 25 ml re-
actionmixturesusingSYBRGreen IQsupermix (Bio-Rad,Hercu-
les, CA) according to the manufacturer’s instructions.
Expression levels of ARwere normalized to b-actin. The exper-
iment was performed three times in duplicate.
2.8. Western blot analysis
Whole cell and tissue protein extracts were resolved on
SDSePAGE using procedures previously reported (Nadiminty
et al., 2008; Nakamura et al., 2011). Proteins were then trans-
ferred to nitrocellulose membrane. After blocking for 1 h at
room temperature in 5% milk in PBS/0.1% Tween-20, mem-
branes were incubated overnight at 4 C with appropriate pri-
mary antibodies. Following incubation with secondary
antibody, immunoreactive proteins were visualized with an
enhanced chemiluminescence detection system (Amersham
Pharmacia Biotech, Buckinghamshire, England). [AR (441)
(sc-7305, mouse monoclonal antibody, Santa Cruz Biotech-
nology, Santa Cruz, CA); p-AKT1/2/3 (ser 473)-R (sc-7985-R,
rabbit polyclonal antibody, Santa Cruz Biotechnology, Santa
Cruz, CA); AKT (#9272, rabbit polyclonal antibody, Cell
Signaling Technology); Bcl-2 (human specific) (#2872, rabbit
polyclonal antibody, Cell Signaling Technology); Tubulin
(T5168, Monoclonal Anti-a-Tubulin antibody, SigmaeAldrich,
St. Louis, MO)]. Tubulin was used to monitor the amounts of
samples applied. The density of the blot bands was quantified
using ImageJ software (National Institutes of Health,
Bethesda, MD, USA; http://rsb.info.nih.gov/ij/).
2.9. Microarray analysis for gene expression profiles
Total RNA was extracted from xenograft tissues using a
mirVanamiRNA Isolation Kit (Life Technologies, Burlington,
ON, Canada) according to the manufacturer’s instructions.
The quality of the RNAwas assessed with an Agilent 2100 bio-
analyzer (Agilent, Santa Clara, CA); batches with an RNA
integrity number value 8.0 were considered acceptable for
microarray analysis. Samples were prepared following Agi-
lent’s One-Color Microarray-Based Gene Expression Analysis
Low Input Quick Amp Labeling v6.0 (Agilent). An input of
100 ng of total RNA was used to generate cyanine-3-labeled
cRNA. Samples were hybridized on Agilent SurePrint G3 Hu-
man GE 8 60KMicroarray v2 (Design ID 039494). Then, arrays
were scanned with the Agilent DNA Microarray Scanner at a
3 mm scan resolution and the data processed with Agilent
Feature Extraction 11.0.1.1. Processed green signal was quan-
tile normalized with Agilent GeneSpring 12.0. RNA quality
control and microarray analysis were performed by the Labo-
ratory for Advanced Genome Analysis at the Vancouver
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analyses were carried out in duplicate. The microarray gene
expression data have been deposited in NCBI’s Gene Expres-
sion Omnibus (GEO, www.ncbi.nlm.nih.gov/geo/) under
accession number GSE48667.
2.10. Microarray data analysis
Microarray probe expression data were filtered for improved
quality prior to downstream analysis. Specifically, probes
without corresponding gene annotations and probes without
detectable expression levels (less than 4 in log2 scale) were
removed. Genes of treated tissues were considered differen-
tially expressed relative to corresponding genes in non-
treated, control tissues if their probes showed 2-fold differ-
ence. Pathway enrichment analysis was performed on such
differentially expressed genes using Ingenuity Pathway Anal-
ysis software (IPA; Ingenuity Systems, Inc., Redwood City, CA).
Statistical over-representation of canonical pathways in the
drug-response-expression signatures was calculated using
the Fischer’s exact test and Benjamini-Hochberg (BH)
multiple-test correction method (Savli et al., 2008; Solskov
et al., 2012), and pathways with a BH-adjusted p-value<0.05
were considered significant. Differentially expressed genes
in “docetaxel þ Aneustat”-treated tissues, compared to con-
trols, were linked to mechanism-based therapeutic targets,
and the linkages of genes and functions were verified in the
literature.
2.11. Statistics
Statistical analyses of gene expression data were performed
as described above, otherwise the Student’s t-test was used.
Results were considered statistically significant when
p < 0.05 and are expressed as means  SEM.Figure 1 e Effects of Aneustat, docetaxel and docetaxel D Aneustat on th
incubated for 48 h with Aneustat and docetaxel at the concentrations and c
indicated by the horizontal line. (A) Cell population at 48 h. The asterisk ind
relative to control.3. Results
3.1. Effects of Aneustat, docetaxel and combinations of
the drugs on growth of human C4-2 prostate cancer cell
cultures
As shown in Figure 1A and B, Aneustat markedly inhibited C4-
2 cell population growth in a dose-dependent manner,
showing inhibitions at hr 48 of 42% and 83% at concentrations
of 50 and 100 mg/ml, respectively ( p < 0.05). Docetaxel at 1 nM
had only aminor effect on C4-2 culture growth, showing an in-
hibition of 21%. Combinations of docetaxel (1 nM) þ Aneustat
(50 mg/ml) and docetaxel (1 nM) þ Aneustat (100 mg/ml) led to
growth inhibitions of 63% and 93%, respectively ( p < 0.05),
indicating that the growth inhibitions of the drug combina-
tions were essentially additive in nature.3.2. Effects of docetaxel þ Aneustat on growth of LTL-
313H prostate cancer xenografts: synergistic growth
inhibition
In preliminary experiments it was found that the maximum
tolerated dose of orally administered Aneustat (used in combi-
nation with docetaxel) was 1652 mg/kg body weight for NOD-
SCID mice at Q1d  5/3.
Groups of NOD-SCID mice bearing LTL-313H xenografts
with an average tumor volume of about 32 mm3 (as indicated
by plasma PSA levels) were treated for 3 weeks with docetaxel
and Aneustat as single agents and with combinations of the
two drugs, using a fixed sub-therapeutic dosage of docetaxel
(5 mg/kg body weight) and increasing dosages of Aneustat
(see Figure 2). The final average tumor volume in the control
group was 133  21 mm3 (mean  SEM). Treatment of the
mice with Aneustat (1652 mg/kg), the maximum toleratede growth of human C4-2 prostate cancer cell cultures. Cells were
ombinations indicated; initial cell concentration, 10 3 104 cells/ml, as
icates p< 0.05 (relative to control). (B) Percentage growth inhibition
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with docetaxel (5 mg/kg) inhibited tumor growth by 51%
( p < 0.05). Aneustat significantly increased the growth-
inhibitory effect obtained with 5 mg/kg docetaxel in a dose-
dependent fashion to 81%, 100% and 106%, at Aneustat dos-
ages of 413, 826 and 1652 mg/kg, respectively ( p < 0.05). The
combination of docetaxel and the highest dosage of Aneustat
(1652 mg/kg) caused complete growth inhibition coupled to
significant tumor volume shrinkage ( p< 0.05) with a T/C value
of 6.1% (Figure 2). The data indicate that Aneustat enhanced
the anticancer in vivo effect of docetaxel in a synergistic
fashion. No major change in appearance and behavior of the
animals was observed during the experiments, nor significant
organ damage at the endpoint, indicating that the treatments
were quite well tolerated by the tumor-bearing mice.3.3. Docetaxel þ Aneustat treatment leads to increased
apoptosis in LTL-313H xenografts
Histopathological analysis of H&E-stained tumor tissue sec-
tions (Figure 3AeD) showed regularmitotic activity in the con-
trol tumors as well as sporadic areas of local necrosis,
presumably due to the fast growth of the tumors. The tumors
treated with Aneustat or docetaxel as single agents showed
elevated numbers of cells arrested in the early phase of
mitosis. In contrast, the tumors treated with both docetaxel
and the highest Aneustat dosage (1652 mg/kg) exhibited
higher amounts of stroma and necrosis area, but few cells
could be seen in mitosis.
Caspase 3 expression, used as an indicator of apoptotic ac-
tivity (Figure 3EeH), indicated that docetaxel and Aneustat
alone, or docetaxel in combination with the low and medium
dosages of Aneustat, only slightly increased apoptosis; in
contrast, docetaxel in combination with the highest AneustatFigure 2 e Effects of a 3-week treatment with Aneustat, docetaxel,
and combinations of the two drugs, on the growth of LTL-313H
prostate cancer xenografts. The average volume of the xenografts at
the start of treatment was approximately 32 mm3 (indicated by the
horizontal line). Control (DMSO); Aneustat (1652 mg/kg; Q1d 3 5/
3); Docetaxel (5 mg/kg; i.p., Q7d/3); Combination low, docetaxel
(5 mg/kg)D Aneustat (413 mg/kg); Combination medium, docetaxel
(5 mg/kg) D Aneustat (826 mg/kg); Combination high, docetaxel
(5 mg/kg) D Aneustat (1652 mg/kg). Data are presented as tumor
volume (mean ± SEM). The asterisks indicate p< 0.05 relative to
control.dosage substantially enhanced caspase-dependent apoptosis
relative to the control (207%) and to apoptosis induced by
docetaxel alone (117%) (Figure 3I; p < 0.05).3.4. Aneustat inhibits AR expression and AKT
phosphorylation in C4-2 cells; synergistic effect of
docetaxel þ Aneustat in LTL-313H xenografts
We investigated the effect of the drugs on expression of AR, a
major factor in prostate cancer growth (Heinlein and Chang,
2004) and on AKT signaling which plays a critical role in the
progression of the disease (Sarker et al., 2009). As shown in
Figure 4A, AR mRNA expression in C4-2 cells was markedly
inhibited by Aneustat (100 mg/ml). Densitometric analysis
using ImageJ software of Western blot bands (Figure 4B)
showed that Aneustat caused decreases of 53, 76 and 86% in
the AR expression of C4-2 cells, compared with controls, at
dosages of 50, 100 and 200 mg/ml, respectively. Similarly,
Aneustat inhibited the phosphorylation of AKT by 63 and
89% at dosages of 100 and 200 mg/ml, respectively, as distinct
from the amount of AKT (Figure 4B). A marked effect of Aneu-
stat on Bcl-2 expression, an anti-apoptotic protein that plays a
role in the PI3K/AKT pathway was found only at a concentra-
tion of 200 mg/ml, i.e. 85% inhibition (Figure 4B).
As shown by Western blot and densitometric analysis
(Figure 4C), treatment of LTL-313H xenografts with Aneustat
alone (1652 mg/kg) did not affect AR expression, but slightly
down-regulated AKT phosphorylation (23%). Treatment with
docetaxel alone (5 mg/kg) down-regulated both AR expression
and AKT phosphorylation by 33 and 44%, respectively. Howev-
er, the combination of docetaxel (5 mg/kg) and Aneustat
(1652 mg/kg) markedly inhibited both AR expression (77%)
and AKT phosphorylation (69%) (without affecting the amount
of AKT), indicative of synergistic action of the two drugs.3.5. Treatment of LTL-313H xenografts with docetaxel,
Aneustat and docetaxel þ Aneustat: mechanisms of action
indicated by DNA microarray data analysis
Expression microarray data were obtained from LTL-313H xe-
nografts treated for 3 weeks with docetaxel (5 mg/kg), Aneu-
stat (1652 mg/kg) and docetaxel (5 mg/kg) þ Aneustat
(1652mg/kg), and fromuntreated controls. Genes showing sig-
nificant differential expression (with 2-fold difference) be-
tween untreated and treated xenografts were used for
pathway analysis using Ingenuity Pathway Analysis (IPA) soft-
ware. The results indicate that both single drugs and com-
bined drugs can act through inhibition or stimulation of
canonical pathways (see Table 1). For example, docetaxel
can inhibit cell cycling and promote apoptosis (by boosting
p53 signaling), consistent with established observations (Li
et al., 2004). Aneustat, used as a single drug, stimulates LXR/
RXR activation and serotonin degradation, inhibits cell cycling
and promotes apoptosis. The combination of
‘docetaxel þ Aneustat’ can affect pathways induced by the
drugs acting as single agents, such as inhibition of IGF-1
signaling by docetaxel, or stimulation of LXR/RXR activation
by Aneustat. But more importantly, it can also act on path-
ways not observably influenced by the drugs used as single
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 3 1 1e3 2 2316agents, such as the metabolic pathways of cholesterol biosyn-
thesis, glycolysis I and gluconeogenesis I.
3.6. Docetaxel þ Aneustat treatment of LTL-313H
xenografts affects genes involved in cancer hallmarks
Genes showing significant (2-fold) changes in expression in
response to treatment of the xenografts with
‘docetaxel þ Aneustat’ were categorized based on their roles
in the hallmarks of cancer. Figure 5A shows that the combined
drug treatment affects most major aspects of cancer develop-
ment. Thus the drug combination down-regulated genes pro-
moting cell proliferation, facilitating cell invasion and
metastasis, inducing angiogenesis and enhancing aerobic
glycolysis; it up-regulated genes promoting cell apoptosis.
Figure 5B shows a down-regulatory effect of the combined
drug treatment on the expression of genes involved in aerobic
glycolysis, a major hallmark of cancer (Vander Heiden et al.,
2009). A comprehensive list of differentially expressed genes
is presented in the Supplementary Table S2.4. Discussion
The present study was aimed at determining, in preclinical
studies, whether the efficacy of docetaxel-based prostateFigure 3 e Effects of a 3-week treatment with Aneustat and docetaxel, used
LTL-313H xenografts as revealed by caspase 3 expression. AeD: tissue sec
arrows point at dying cells; EeH: tissue sections stained for caspase 3; magn
asterisks indicate p< 0.05 relative to control.cancer therapy could be enhanced by combining docetaxel
with Aneustat (OMN54), a multivalent botanical drug candi-
date that is currently assessed in a Phase-I Clinical Trial
(NCTId: NCT01555242). Although docetaxel-based therapy
currently represents the best available treatment for highly
advanced metastatic prostate cancer, it only marginally ex-
tends patients’ lives (McKeage, 2012; Tannock et al., 2004).
Drug development efforts have therefore focussed on
improvement of its efficacy by combining docetaxel with a
wide variety of anticancer agents. However, as recently
pointed out in an editorial (Antonarakis and Eisenberger,
2013), Phase III clinical trials using docetaxel-based combina-
tions for metastatic castration-resistant prostate cancer have
so far failed to demonstrate an improvement in patient sur-
vival, in spite of indications by preclinical studies that the ef-
ficacy of docetaxel was enhanced by the drug combinations.
Such a discrepancy between drug efficacies established in
the clinic and those predicted by preclinical studies is very
evident for new, potential anticancer agents. Thus only w5%
of anticancer drug candidates, that have successfully passed
required preclinical in vivo efficacy screening tests, have sig-
nificant effectiveness in clinical trials and are approved for
clinical usage by the U.S. Food & Drug Administration
(Kummar et al., 2007; Sharpless and Depinho, 2006). It has
become apparent that preclinical assessment of clinical effi-
cacy of anticancer drugs is seriously hampered by a lack ofas single agents or in combination (see legend Fig. 2), on apoptosis in
tions stained with H&E, black arrows point at mitotic figures, white
ification 3 400. I: Relative caspase 3 expression (means ± SEM). The
MO L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 3 1 1e3 2 2 317clinically relevant, experimental in vivo cancermodels. Subcu-
taneous cancer cell line xenograft models, commonly used for
preclinical in vivo drug efficacy tests, do not adequately predict
the efficacy of anticancer agents in the clinic (Johnson et al.,
2001; Kamb, 2005; Leaf, 2004; Sharpless and Depinho, 2006).
To assess the effect of combining docetaxel with Aneustat,
we therefore did not only make use of C4-2 cell cultures, but
especially of NOD-SCID mice carrying xenografts of a trans-
plantable LTL-313H prostate cancer tissue xenograft line.
Thismetastatic, PTEN-deficient, PSA-secreting line was devel-
oped from a patient’s primary prostatic adenocarcinoma
(Watahiki et al., 2011), using subrenal capsule graftingFigure 4 e Effect of Aneustat and docetaxel on AR expression and
AKT phosphorylation. (A) Effect of a 24-h treatment of C4-2 cell
cultures with Aneustat on AR mRNA expression (by qPCR) and (B)
on AR protein expression, AKT phosphorylation and amount of
AKT. (C) Effect of a 3-week treatment of LTL-313H xenografts with
Aneustat (1652 mg/kg), docetaxel (5 mg/kg) and a combination of
docetaxel (5 mg/kg) D Aneustat (1652 mg/kg) on AR protein
expression, AKT phosphorylation and amount of AKT.technology that tends to preserve important properties of
the original cancers, including histopathology, chromosomal
aberrations, gene expression profiles and 3-dimensional ar-
chitecture of the malignancy (Collins et al., 2012; Tung et al.,
2011; Wang et al., 2005a, 2005b) thus rendering high clinical
relevance to this advanced prostate cancer model. The use
of this model in the present study therefore increases the like-
lihood that the results obtained are useful.
In contrast to the marked inhibitory effect of Aneustat
alone on the replication of C4-2 cells in vitro (Figure 1), the
treatment of LTL-313H xenografts with Aneustat alone during
a 3-week period (dosage: 1652mg/kg at Q1d 5/3) was not sta-
tistically significant (Figure 2). However, the combination of
Aneustat with docetaxel (5 mg/kg) markedly increased the in-
hibition of the growth of xenografts obtained with docetaxel
alone (Figure 2). Even the lowest in vivo dosage of Aneustat
(413 mg/kg), used in combination with docetaxel, resulted in
a 30% increase in the growth-inhibitory effect obtained with
docetaxel alone ( p < 0.05; Figure 2). The synergistic enhance-
ment of anticancer activity by the combination of docetaxel
and Aneustat is particularly evident from the complete inhibi-
tion of the growth of the LTL-313H xenografts and their
shrinkage (T/C ¼ 6.1%) resulting from treatment with Aneu-
stat (at 1652 mg/kg) in combination with docetaxel used at
5 mg/kg body weight, a sub-therapeutic dosage (Figure 2).
The tumor shrinkage was associated with an increase in
apoptotic activity (Figure 3H,I), an effect not observed when
docetaxel or Aneustat were used as single agents (Figure 3I).
Importantly, the combination of docetaxel and Aneustat was
quite well tolerated by the animals. The data suggest that
docetaxel-based treatment of advanced prostate cancer may
be enhanced by using docetaxel in combination with
Aneustat.
It is not clear why Aneustat and docetaxel had synergistic
growth-inhibitory effects in vivo, but not in vitro (Figures 1
and 2). The synergism of the drugs in vivo may be a reflection
of the much greater biological complexity of the in vivo situa-
tion, including the presence of a variety of host cells and or-
gans that could modulate the actions of the drugs and their
interactions with target cells.
The mechanism by which the combination of docetaxel
and Aneustat enhances the anticancer activity in vivo is ofma-
jor interest for potential improvement of docetaxel-based
therapy of advanced prostate cancer. Its elucidation requires
an understanding of the molecular actions of both drugs, in
particular when they are used in combination. Docetaxel is
well known for its interference with microtubule assembly/
disassembly to cause growth arrest and induction of apoptosis
(Pienta, 2001; Stein, 1999; Tabaczar et al., 2010), as also
observed in the present study using LTL-313H prostate cancer
xenografts (Figures 2 and 3). These mechanisms of docetaxel
action are confirmed in our gene expression profiling analysis
of the docetaxel-treated xenografts (Table 1), indicating that
the reductive effects of docetaxel on the xenografts are based
on inhibition of cyclins and cell cycle regulation and also on
stimulation of p53 signaling, a process that may lead to
apoptosis (Liu et al., 2013). Furthermore, it has been reported
that docetaxel can down-regulate AR expression in prostate
cancer (Kuroda et al., 2009), an observation which was
confirmed in the present study (Figure 4C).
Table 1 e Pathways stimulated ([) or inhibited (Y) in LTL-313H
xenografts by treatment with docetaxel (5 mg/kg), Aneustat
(1652 mg/kg) and docetaxelD Aneustat as predicted by Ingenuity
Pathway Analysis of DNA microarray data.
Pathways Docetaxel Aneustat Combination
Mitotic roles
of polo-like Kinase
e e Y
Cell cycle control
of chromosomal
replication
e e Y
ATM signaling e e Y
Role of CHK proteins
in cell cycle
checkpoint control
e e Y
LXR/RXR activation e [ [
Serotonin degradation e [ e
Cyclins and cell
cycle regulation
Y Y Y
GADD45 signaling [ [ [
Cholesterol
biosynthesis
e e Y
Glycolysis I e e Y
Gluconeogenesis I e e Y
Cell Cycle:
G1/S checkpoint
regulation
Y Y Y
p53 signaling [ [ [
Mitochondrial
dysfunction
Y Y Y
IL-8 signaling Y Y Y
IGF-1 signaling Y e Y
ILK signaling Y e e
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molecular mechanisms of action of Aneustat. Our study indi-
cates e for the first time e that Aneustat can induce apoptosis
(Figure 3), as well as inhibit AR expression, AKT phosphoryla-
tion and Bcl-2 expression (Figure 4), processes that play
important roles in the malignant progression of prostate can-
cer and its chemoresistance (Guyader et al., 2012; Mulholland
et al., 2006; Xin et al., 2006). The gene expression profiling of
Aneustat-treated xenografts (Table 1) suggests stimulation
of LXR/RXR activation as an action of Aneustat. This sugges-
tion is supported by the finding that Aneustat reduced AKT
phosphorylation of C4-2 prostate cancer cells (Figure 4B), as
LXR activation has been reported to down-regulate AKT phos-
phorylation in prostate cancer cells (Pommier et al., 2010). The
gene expression analysis also suggests stimulation of seroto-
nin degradation as another action of Aneustat (Table 1).
Studies have shown that growth of prostate cancer cells can
be interrupted by inhibiting the synthesis and metabolism of
serotonin, a neurotransmitter that plays a role as a growth
factor for prostate cancer cells (Dizeyi et al., 2011; Shinka
et al., 2011). Additional experimental verification will be
needed to establish these mechanistic properties of Aneustat.
It may be noted that although Aneustat on its own did not
significantly inhibit the growth of the LTL-313H cancer tissue
xenografts that were grafted under renal capsules, itmarkedly
suppressed the growth of e.g., subrenal LNCaP cell line xeno-
grafts (Supplementary Figure S1), consistent with the
growth-inhibitory effects of Aneustat on C4-2 cells in vitro(Figure 1). Further studies are needed to determine the basis
of these differences in the in vivo growth-inhibitory activities
of Aneustat.
Notably, treatment of the prostate cancer xenografts with
the ‘docetaxel þ Aneustat’ combination inhibited critical can-
cer pathways that were not affected by the individual drugs,
such as cholesterol biosynthesis, glycolysis I and gluconeo-
genesis (Table 1). Cholesterol has an emerging role in prostate
cancer as a potential therapeutic target, as intracellular
cholesterol has recently been found to promote prostate can-
cer progression through regulation of AKT signaling and as a
substrate for de novo androgen synthesis (Lee et al., 2013;
Pelton et al., 2012). The inhibitions of glycolysis I and gluco-
neogenesis I are of special interest, since these two pathways
have important roles in “reprogrammed energy metabolism”,
a key hallmark of cancer (Hanahan and Weinberg, 2011).
Expression microarray profiling of the xenografts confirmed
that the majority of the genes involved in the glycolysis
pathway were indeed down-regulated by the
docetaxel þ Aneustat treatment (Figure 5B). Taken together,
the data suggest that the increased anti-tumor activity of
the docetaxel þ Aneustat combination is based on an expan-
sion of anticancer activity, targeting multiple pathways and
hallmarks of cancer, not attainable with the single drugs.
The effect of docetaxelþ Aneustat on glycolysis is of major
interest, since treatment with this drug combination could
lead to a reduction in lactic acid secretion by cancers. As
recently reviewed by us (Choi et al., 2013), there is increasing
evidence that cancer cells can suppress the anticancer im-
mune response through maintaining a relatively low pH in
their micro-environment via regulation of their lactic acid
secretion. They are thought to achieve this via modification
of glucose/glutaminemetabolisms. Treatment targeting these
metabolisms could reduce lactic acid secretion of cancers and
increase the pH of the tumor micro-environment to more
normal levels. This would lead to restoration of the local anti-
cancer immune response. It appears from these consider-
ations that treatment with docetaxel þ Aneustat could not
only affect cancers by direct drug-cancer cell interactions,
but also indirectly, i.e. in immuno-competent hosts, through
restoring the immune response in the cancer micro-
environment.
It is generally accepted that cancers have an ability to
circumvent therapy by switching from a targeted pathway to
a different one (Hanahan and Weinberg, 2011). The combina-
tion of docetaxel þ Aneustat may also interfere with this pro-
cess by targeting multiple aspects of cancer (Figure 5, Table 1)
and hence reduce the probability for the disease to evade a
particular therapeutic approach by switching to other
pathways.
AR and AKT signaling are important processes underlying
prostate cancer growth (Xin et al., 2006). Inhibition of both
AR expression and AKT signaling is apparently required to
obtain near-complete regression of PTEN-deficient prostate
cancers (Carver et al., 2011; Oh et al., 2012). The LTL-313H
xenograft tissue line used in this study is deficient in PTEN
(Wu et al., 2012) and the finding that treatment of the xeno-
grafts with docetaxel þ Aneustat, as distinct from the single
agents, led to complete inhibition of tumor growth coupled
to tumor shrinkage, is consistent with inhibition of both
Figure 5 e Effects of treatment of LTL-313H xenografts with docetaxelD Aneustat on expression of cancer hallmark-mediating genes as revealed
via DNA microarray analysis. (A) Up-regulated (red) and down-regulated (blue) genes. (B) Down-regulated (green) glycolysis-associated genes.
Additional information is presented in the Supplementary Table S2.
MO L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 3 1 1e3 2 2 319AR expression and AKT phosphorylation in xenografts ob-
tained only in the case of the combined drug treatment
(Figure 4C).
In conclusion, the present study has shown, for the first
time, that the combination of docetaxel and Aneustat can
markedly and synergistically enhance the anticancer activity
in a highly clinically relevant advanced prostate cancermodel.
The enhanced efficacy appears to be based on expanded anti-
cancer activity, targeting multiple pathways and hallmarks of
cancer, which results from the combination of docetaxel andAneustat. The data suggest that docetaxel-based therapy of
advanced human prostate cancer may be improved by using
docetaxel in combination with Aneustat.Grant support
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